{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:29:25Z","timestamp":1784867365558,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T00:00:00Z","timestamp":1460764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00432-016-2155-y","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T08:31:37Z","timestamp":1460795497000},"page":"1441-1447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study"],"prefix":"10.1007","volume":"142","author":[{"given":"Michael","family":"Lauseker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"key":"2155_CR1","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M et al (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29:2514\u20132520. doi: 10.1200\/jco.2011.34.7146","journal-title":"J Clin Oncol"},{"key":"2155_CR2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10552-013-0204-2","volume":"24","author":"T Blakely","year":"2013","unstructured":"Blakely T, Barendregt JJ, Foster RH, Hill S, Atkinson J, Sarfati D, Edwards R (2013) The association of active smoking with multiple cancers: national census-cancer registry cohorts with quantitative bias analysis. Cancer Causes Control 24:1243\u20131255. doi: 10.1007\/s10552-013-0204-2","journal-title":"Cancer Causes Control"},{"key":"2155_CR3","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.13045","volume":"93","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D (2008) Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica 93:1544\u20131549. doi: 10.3324\/haematol.13045","journal-title":"Haematologica"},{"key":"2155_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.leukres.2013.10.023","volume":"38","author":"CR Cogle","year":"2014","unstructured":"Cogle CR et al (2014) High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk Res 38:71\u201375. doi: 10.1016\/j.leukres.2013.10.023","journal-title":"Leuk Res"},{"issue":"Suppl 2","key":"2155_CR5","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1007\/s00277-015-2313-3","volume":"94","author":"A Gratwohl","year":"2015","unstructured":"Gratwohl A, Baldomero H, Passweg J (2015) The role of hematopoietic stem cell transplantation in chronic myeloid leukemia. Ann Hematol 94(Suppl 2):S177\u2013S186. doi: 10.1007\/s00277-015-2313-3","journal-title":"Ann Hematol"},{"issue":"Suppl 2","key":"2155_CR6","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1007\/s00277-015-2331-1","volume":"94","author":"R Hehlmann","year":"2015","unstructured":"Hehlmann R (2015) CML\u2014where do we stand in 2015? Ann Hematol 94(Suppl 2):S103\u2013S105. doi: 10.1007\/s00277-015-2331-1","journal-title":"Ann Hematol"},{"key":"2155_CR7","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS et al (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 29:1336\u20131343. doi: 10.1038\/leu.2015.73","journal-title":"Leukemia"},{"key":"2155_CR8","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M et al (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 122:1284\u20131292. doi: 10.1182\/blood-2013-04-495598","journal-title":"Blood"},{"issue":"Suppl 2","key":"2155_CR9","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M Hoglund","year":"2015","unstructured":"Hoglund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94(Suppl 2):S241\u2013S247. doi: 10.1007\/s00277-015-2314-2","journal-title":"Ann Hematol"},{"key":"2155_CR10","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123\u20133127. doi: 10.1002\/cncr.26679","journal-title":"Cancer"},{"key":"2155_CR11","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1158\/1055-9965.EPI-13-0093","volume":"22","author":"GC Kabat","year":"2013","unstructured":"Kabat GC, Wu JW, Moore SC, Morton LM, Park Y, Hollenbeck AR, Rohan TE (2013) Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP Diet and Health Study. Cancer Epidemiol Biomarkers Prev 22:848\u2013854. doi: 10.1158\/1055-9965.epi-13-0093","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2155_CR12","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H et al (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119:1981\u20131987. doi: 10.1182\/blood-2011-08-358135","journal-title":"Blood"},{"key":"2155_CR13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035. doi: 10.1016\/s1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"2155_CR14","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/cncr.28641","volume":"120","author":"ZK McQuilten","year":"2014","unstructured":"McQuilten ZK et al (2014) Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 120:1686\u20131694. doi: 10.1002\/cncr.28641","journal-title":"Cancer"},{"key":"2155_CR15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00103-013-1869-0","volume":"57","author":"A Nennecke","year":"2014","unstructured":"Nennecke A, Wienecke A, Kraywinkel K (2014) Leukemia incidence and survival in Germany according to current standardized categories. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57:93\u2013102. doi: 10.1007\/s00103-013-1869-0","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2155_CR16","author":"L Ohm","year":"2014","unstructured":"Ohm L et al (2014) Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma. doi: 10.3109\/10428194.2014.953141","journal-title":"Leuk Lymphoma"},{"key":"2155_CR17","volume-title":"Bev\u00f6lkerung Deutschlands bis 2060. 13. koordinierte Bev\u00f6lkerungsvorausberechnung","author":"O P\u00f6tzsch","year":"2015","unstructured":"P\u00f6tzsch O, R\u00f6\u00dfger F (2015) Bev\u00f6lkerung Deutschlands bis 2060. 13. koordinierte Bev\u00f6lkerungsvorausberechnung. Statistisches Bundesamt, Weisbaden"},{"key":"2155_CR18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-6-70","volume":"6","author":"D Pulte","year":"2013","unstructured":"Pulte D et al (2013) Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. J Hematol Oncol 6:70. doi: 10.1186\/1756-8722-6-70","journal-title":"J Hematol Oncol"},{"key":"2155_CR19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ejh.12468","volume":"94","author":"D Pulte","year":"2015","unstructured":"Pulte D, Redaniel MT, Bird J, Jeffreys M (2015) Survival for patients with chronic leukemias in the US and Britain: age-related disparities and changes in the early 21st century. Eur J Haematol 94:540\u2013545. doi: 10.1111\/ejh.12468","journal-title":"Eur J Haematol"},{"key":"2155_CR20","doi-asserted-by":"crossref","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","volume":"4","author":"AG Smith","year":"2014","unstructured":"Smith AG et al (2014) Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open 4:e004266. doi: 10.1136\/bmjopen-2013-004266","journal-title":"BMJ Open"},{"key":"2155_CR21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd2873","volume":"8","author":"S Storey","year":"2009","unstructured":"Storey S (2009) Chronic myelogenous leukaemia market. Nat Rev Drug Discov 8:447. doi: 10.1038\/nrd2908","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2155-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2155-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2155-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T19:38:16Z","timestamp":1567798696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2155-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,16]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["2155"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2155-y","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,16]]}}}